CLINICAL_TRIALS
trial_result
· 2024-11-20
Clinical Trial Update: Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema [Phase 2]
Summary
A Phase 2 trial evaluating suprachoroidal administration of Triesence for diabetic macular edema has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Oxular Limited | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED | Results posted: 2024-11-20